News | Embolic Protection Devices | May 08, 2018

Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent

Device captures debris in 99 percent of patients undergoing TAVR

Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent

May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of stroke during transcatheter aortic valve replacement (TAVR) by more than 60 percent. Since its clearance by the U.S. Food and Drug Administration (FDA) a year ago, the technology is now used by more than 10 percent of TAVR centers nationwide, according to manufacturer Claret Medical.

The Sentinel Cerebral Protection System protects patients by filtering, capturing and removing pieces of tissue, calcium and other harmful debris released during TAVR before it can reach the brain. Such debris could cause a blockage, potentially leading to a stroke. Studies have shown that the Sentinel technology captures debris in 99 percent of patients undergoing TAVR and has no safety risks associated with it.

Sentinel patient Jim McCutchon of Corpus Christi, Texas said, “Having aortic stenosis is like flirting with sudden death. My aortic valve was closing down slowly, and I had to stop to catch my breath even with no greater exercise than a leisurely walk. I needed TAVR, but I was concerned that I would have a stroke if I had TAVR without cerebral protection. I struggled with a three-year wait until Sentinel was available, and then I felt confident to move forward with the procedure. I’ve seen pictures of the debris that Sentinel captured on the way to my brain, and I am thankful that I waited. Since then, I have had no problems, and I can run and play again.”

“We would never drive a car without a seatbelt and we should never do TAVR without embolic protection,” said Susheel Kodali, M.D., from New York-Presbyterian Hospital.

“Stroke destroys lives, and it is important that we as physicians do all we can to prevent it. With this in mind, we now use Sentinel technology in all our TAVR cases and have been able to provide greater brain protection to patients,” said Samir Kapadia, M.D., with the Cleveland Clinic.

For more information: www.claretmedical.com

 

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...